Gaboksadol

Gaboksadol
Klinički podaci
AHFS/Drugs.com Monografija
Identifikatori
CAS broj 64603-91-4
ATC kod nije dodeljen
PubChem[1][2] 3448
ChemSpider[3] 3330
UNII K1M5RVL18S DaY
KEGG[4] D04282 DaY
ChEMBL[5] CHEMBL312443 DaY
Hemijski podaci
Formula C6H8N2O2 
Mol. masa 140,140
SMILES eMolekuli & PubHem
InChI
InChI=1S/C6H8N2O2/c9-6-4-1-2-7-3-5(4)10-8-6/h7H,1-3H2,(H,8,9)
Key: ZXRVKCBLGJOCEE-UHFFFAOYSA-N DaY
Farmakoinformacioni podaci
Trudnoća ?
Pravni status

Gaboksadol je organsko jedinjenje, koje sadrži 6 atoma ugljenika i ima molekulsku masu od 140,140 Da.

Osobine

Osobina Vrednost
Broj akceptora vodonika 3
Broj donora vodonika 2
Broj rotacionih veza 0
Particioni koeficijent[6] (ALogP) 0,3
Rastvorljivost[7] (logS, log(mol/L)) -0,6
Polarna površina[8] (PSA, Å2) 58,3

Reference

  1. Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519.  edit
  2. Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1. 
  3. Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846.  edit
  4. Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H. 
  5. Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594.  edit
  6. Ghose, A.K., Viswanadhan V.N., and Wendoloski, J.J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragment Methods: An Analysis of AlogP and CLogP Methods”. J. Phys. Chem. A 102: 3762-3772. DOI:10.1021/jp980230o. 
  7. Tetko IV, Tanchuk VY, Kasheva TN, Villa AE. (2001). „Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices”. Chem Inf. Comput. Sci. 41: 1488-1493. DOI:10.1021/ci000392t. PMID 11749573. 
  8. Ertl P., Rohde B., Selzer P. (2000). „Fast calculation of molecular polar surface area as a sum of fragment based contributions and its application to the prediction of drug transport properties”. J. Med. Chem. 43: 3714-3717. DOI:10.1021/jm000942e. PMID 11020286. 

Literatura

  • Hardman JG, Limbird LE, Gilman AG. (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10 izd.). New York: McGraw-Hill. DOI:10.1036/0071422803. ISBN 0-07-135469-7. 
  • Thomas L. Lemke, David A. Williams, ur. (2007). Foye's Principles of Medicinal Chemistry (6 izd.). Baltimore: Lippincott Willams & Wilkins. ISBN 0-7817-6879-9. 

Spoljašnje veze

Portal Medicina
Portal Hemija
Gaboksadol na Wikimedijinoj ostavi
  • Gaboxadol
  • p
  • r
  • u
GABAA receptor
Ultra kratkotrajni
Kratko/srednje
trajni
Dugotrajni
Negrupisani
Kratkotrajni
Intermedijerno trajni
Dugotrajni
Dialkil-fenoli
CL-218,872 • Eszopiklon • Indiplon • Nekopidem • Pazinaklon • ROD-188 • Saripidem • Suproklon • Suriklon • SX-3228 • U-89843A • U-90042 • Zaleplon • Zolpidem • Zopiklon
Neuroaktivni
steroidi
Alfa-2 adrenergički
receptor
Melatoninski receptor
Histaminski receptor &
Acetilholinski receptor
5-HT2A &
α1- adrenergički
Selektivni 5-HT2A & α1-adrenergički antagonisti
GABAB receptor /
GHB receptor
GHB Tip
Oreksinski receptori
Oreksinski antagonisti
Drugi receptori/
negrupisani
Drugi
2-Metil-2-butanol • Acekarbromal • Acetofenon • Apronal • Bromidi • Bromizoval • Karbromal • Hloralosa • Klometiazol • Embutramid • Etomidat • Evoksin • Fenadiazol • Gaboksadol • Loreklezol • Mefenoksalon • Sulfonmetan • Trihloroetanol • Triklofos • Valerian • Valnoktamid

M: PSO/PSI

mepr

dsrd (o,d,b,p,a,s), spes, spvo

proc, lek(N5A/5B/5C/6A/6B/6D)